MAPK activation predicts poor outcome and the MEK inhibitor, selumetinib, reverses antiestrogen resistance in high grade serous ovarian cancer

OBJECTIVE: While 67% of high grade serous ovarian cancers (HGSOC) express the estrogen receptor (ER), most fail antiestrogen therapy. Since mitogen-activated protein kinases (MAPK) activation is frequent in ovarian cancer, we investigated if estrogen regulates MAPK and if MEK inhibition (MEKi) rever...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Clin Cancer Res
Egile Nagusiak: Hew, Karina E., Miller, Philip C., El-Ashry, Dorraya, Sun, Jun, Besser, Alexandra H., Ince, Tan A., Gu, Mengnan, Wei, Zhi, Zhang, Guo, Brafford, Patricia, Gao, W., Lu, Yiling, Mills, Gordon B., Slingerland, Joyce M., Simpkins, Fiona
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2015
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4755805/
https://ncbi.nlm.nih.gov/pubmed/26482043
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-0534
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak